Premium
TSLC1 tumour‐suppressor gene expression in canine mast cell tumours
Author(s) -
Taylor F.,
Murphy S.,
Hoather T.,
Dobson J.,
Scase T.
Publication year - 2010
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2010.00220.x
Subject(s) - immunohistochemistry , pathology , lung cancer , mast cell , tumor suppressor gene , staining , gene expression , medicine , biology , gene , immunology , cancer , carcinogenesis , genetics
Tumour suppressor in lung cancer‐1 (TSLC1) is a tumour‐suppressor gene coding for an adhesion molecule that is expressed by mast cells. Reduced TSLC1 expression is associated with a poor prognosis in several human tumours, and this study sought to investigate if TSLC1 expression could be used to predict outcome in dogs with mast cell tumours (MCTs). Sections of MCTs of different tumour grades from 45 dogs (Group 1) were immunohistochemically assessed for TSLC1 and Ki67 expression. In addition, 35 intermediate‐grade MCTs (Group 2) from dogs with known clinical follow‐up were immunohistochemically stained for TSLC1 and Ki67. The TSLC1 staining intensity was found to strongly inversely correlate with tumour grade for Group 1 ( P = 0.002857). For Group 2 there was a trend towards dogs with lower TSLC1 scores being more likely to die from MCT‐related disease ( P = 0.058). The intensity of TSLC1 staining inversely correlated with Ki67 expression for both groups.